Cell senescence is defined by the irreversible loss of proliferative capacity in cells that can normally divide. Cell senescence is driven by exhaustion of replicative potential, for example, by telomere shortening, or as a stress response -so-called 'stress-induced premature senescence' . Both types of senescence are characterized by withdrawal from the cell cycle and by a number of markers, including upregulation of the cyclin-dependent kinase inhibitor p16 ink4a , and secretion of a panel of cytokines as part of the 'senescenceassociated secretory phenotype' (SASP). In a recent article published in Science, Childs and colleagues showed that atherosclerotic plaques from LDL-receptor null mice contain cells with activity of the pH-sensitive lysosomal enzyme senescence-associated β-galactosidase (SAβG), and mRNA encoding SASP cytokines 1 . SAβG-positive cells had some ultrastructural features of endothelial cells, vascular smooth muscle cells (VSMCs), and macrophages; were present at high concentrations in advanced lesions; and were also found in areas predisposed to atherosclerosis within only 9 days of fat-feeding. The investigators then used transgenic mice containing reporter and/or suicide genes to identify and kill cells on the basis of p16 ink4a promoter activity 1 . Removal of cells with p16 ink4a promoter activity reduced both plaque formation and progression, and promoted some features of stable plaques. These findings suggest that senescence might occur much earlier and be stages of atherosclerosis. Suicide genes driven from a p16 ink4a promoter have been used successfully to define the role of senescent cells in both disease and normal ageing 5 . However, this technique relies on the transgenic p16 ink4a promoter being specific for senescent cells, and not active in other cells (such as plaque macrophages). By contrast, p16 ink4a is expressed in resident and inflammatory macro phages, including macrophage-rich areas of human atherosclerotic plaques 6 , and is also upregulated when monocytes differentiate into macro phages 7 , as occurs in atherosclerosis. p16 ink4a can also regulate macrophage polarization and promote inflammatory signalling in murine macrophages 8 . Mice might possess higher levels of cell senescence in atherosclerosis than humans, because aged mice and fat-fed Apoe −/− mice show an accumulation of telomere-associated DNA damage foci 9 , another surrogate marker of senescence. However, these findings also raise the possibility that what the investigators identified as senescent cells might also be inflammatory macrophages, which are present in very early and advanced lesions. Indeed, macrophage ablation alone reduces plaque development and promotes features of plaque stability, particularly in less advanced lesions 10 . Phagocytic cells have also been shown to have SAβG activity in chronologically aged mice, whereas removal of these cells reduces the p16 ink4a signal in p16 ink4a reporter mice 4 . Together, these observations suggest that macrophages can substantially contribute to SAβG staining, and might be killed via suicide genes driven by p16 ink4a promoters. The precise frequency, lineage, and functional consequences of cell senescence in atherosclerosis thus remains to be determined.
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Mice might possess higher levels of cell senescence in atherosclerosis than humans, because aged mice and fat-fed Apoe −/− mice show an accumulation of telomere-associated DNA damage foci 9 , another surrogate marker of senescence. However, these findings also raise the possibility that what the investigators identified as senescent cells might also be inflammatory macrophages, which are present in very early and advanced lesions. Indeed, macrophage ablation alone reduces plaque development and promotes features of plaque stability, particularly in less advanced lesions 10 . Phagocytic cells have also been shown to have SAβG activity in chronologically aged mice, whereas removal of these cells reduces the p16 ink4a signal in p16 ink4a reporter mice 4 . Together, these observations suggest that macrophages can substantially contribute to SAβG staining, and might be killed via suicide genes driven by p16 ink4a promoters. The precise frequency, lineage, and functional consequences of cell senescence in atherosclerosis thus remains to be determined.
A number of senolytic agents have been developed that selectively kill some types of senescent cells, which can mitigate premature ageing of tissues containing those cells 5 . Genetic ablation of senescent cells can also attenuate age-related deterioration of several organs and prolong lifespan 5 , raising the prospect that senolytic agents might reduce ageing-associated diseases such as atherosclerosis. Indeed, the senolytic combination dasatinib plus quercetin improved acute vasomotor function but not arterial compliance in aged mice, and reduced markers of senescence in the tunica media of fat-fed Apoe −/− mice 9 .
far more frequent than previously thought, that it promotes atherosclerosis through SASP proinflammatory cytokines, and that senolytic drugs might have therapeutic potential in atherosclerosis (FIG. 1) . Several surprising findings were reported by Childs and colleagues that are particularly relevant to the specificity of identification and deletion of senescent cells in atherosclerosis 1 . For example, previous studies have reported that advanced human plaques show evidence of senescence, including telomere shortening and SAβG activity 2 , and that induction of senescence in human VSMCs mediates IL-1α-dependent SASP 3 . However, SAβG is not specific for senescent cells in mice or humans, as it can also mark macrophages 4 . Indeed, most SAβG-positive cells in human plaques seem to be macrophages in the lesion core, with very infrequent intensely-positive VSMCs in the cap that also show other senescence markers such as p16 ink4a , but no evidence of senescence in the tunica media 2, 3 . Similarly, although in the study by Childs and colleagues cell lineage was not precisely identified nor cell proliferation examined, the SASP components used as senescence markers by the investigators, such as matrix metalloproteinases, tumour necrosis factor, and IL-1α 1 , are all highly expressed by macrophages Atherosclerosis is a disease of ageing, and the most common cause of death in the industrialized world. Cell senescence and the therapeutic removal of senescent cells using 'senolytics' are topical areas of science and translational medicine. A new study reports surprising findings on cell senescence and atherosclerosis with important therapeutic implications.
However, dasatinib plus quercetin did not reduce senescence markers in the intima, and had no effect on plaque size or lipid content 9 . Whatever the specificity of the senescence markers or the identity of the deleted cells, this study has important implications for the use of senolytic agents in atherosclerosis. Removal of cells that have p16 ink4a promoter activity reduced plaque development and progression, and promoted features of stability. These effects were seen in multiple vascular beds, in a number of mouse models, and were not due to effects on serum lipids or peripheral blood counts. Local removal of cells that secrete multiple proinflammatory cytokines is an attractive therapeutic goal in the treatment of atherosclerosis. Removal of p16 + /SAβG + macrophages or other cell types that have p16 promoter activity might also be therapeutically useful for a variety of age-associated diseases, or indeed might promote longevity. Ageing has been considered a nonmodifiable risk factor for atherosclerosis; however, these new findings by Childs and colleagues suggest that this might be about to change. 
